



- a company developing evidence-based treatments - specifically for children

Newsletter Jan 2021

WELCOME #1

What is the ambition with Cessatech, who is behind the company and which activities are considered major milestones? This is a short newsletter answering some of these questions 4-6 times a year. Since the successful IPO in December 2020, we have been extremely busy focusing on the business and initiating the clinical preparations. This was needed as an IPO obviously takes up much time - we are very excited with all the activities coming up

MAJOR MILESTONES - the REGISTRY STUDY

We have 3 major milestones anticipated to come out in 2021 - this being the result of 3 clinical trials. Apart from this, we also have a number of smaller milestones, but the Registry Study is something to look forward to. In collaboration with Karolinska Hospital in Sweden, data from more than 10 years of 'off-label' use has been collected, some 2500 procedures from app 250-300 children using CT001 - but not in a fixed ready to use combination. The objective of the study is to investigate safety and tolerability of intranasal sufentanil and ketamine as a free combination in a paediatric cohort aged 1-17. We anticipate the results will be finalized and topline results communicated during Q1 2021.

MEET THE TEAM - Steen Henneberg, M.D, Ph.D. - Chief Medical Officer

This time we give a short introduction to Steen, who studied medicine at the University of Århus, Denmark, and has since then been active at Västerås Hospital, Sweden, Frenchay Hospital, Bristol, UK and University Hospital, Uppsala, Sweden - 101 peer reviewed publications with 62 clinical studies and not to forget, Head of the Department of Paediatric Anaesthesia, Copenhagen University Hospital, Denmark (Rigshospitalet) for 26 years. Steen has also volunteered on 1-2 week missions as anaesthetist in different parts of the world: Quito in Ecuador, Tacloban, Philippines, Phalodi, Rajasthan, India, Cajamarca and Cusco in Peru and in Eritrea, Asmara. Steen is one of the founders and our Chief Medical Officer.



OUR PURPOSE

Rethinking Child Treatments is our business purpose - we want to make a difference for children. We are close to the children at Rigshospitalet and at Karolinska hospital, we have our own children, but we want to ensure that we constantly make a difference, working with bigger medical unmet needs or opportunities. On a more soft-side of the business we have therefore entered an agreement (sponsorship) with Red Barnet (Save the Children) - we will start doing more voluntary work and support where we can. It will be interesting to see where this can take us.



If you are not already following our newsletters, please sign up for more news [here](#)